Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; R… Read more
Radiopharm Theranostics Limited (RDPTF) - Total Liabilities
Latest total liabilities as of December 2024: $40.45 Million USD
Based on the latest financial reports, Radiopharm Theranostics Limited (RDPTF) has total liabilities worth $40.45 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Radiopharm Theranostics Limited - Total Liabilities Trend (2022–2025)
This chart illustrates how Radiopharm Theranostics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Radiopharm Theranostics Limited Competitors by Total Liabilities
The table below lists competitors of Radiopharm Theranostics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
YOC AG
F:YOC
|
Germany | €13.25 Million |
|
Gseven Co Ltd
TWO:2937
|
Taiwan | NT$1.79 Billion |
|
Asia Pacific Wire & Cable Corp Ltd
NASDAQ:APWC
|
USA | $129.09 Million |
|
Xchanging Solutions Limited
NSE:XCHANGING
|
India | ₹1.46 Billion |
|
Petros Petropoulos AEBE
AT:PETRO
|
Greece | €69.41 Million |
|
Mr Bricolage
PA:ALMRB
|
France | €220.49 Million |
|
Sungwoo Electronics Co. Ltd
KQ:081580
|
Korea | ₩46.65 Billion |
|
Credo Brands Marketing Limited
NSE:MUFTI
|
India | ₹3.61 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down Radiopharm Theranostics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Radiopharm Theranostics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Radiopharm Theranostics Limited (2022–2025)
The table below shows the annual total liabilities of Radiopharm Theranostics Limited from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $43.61 Million | -2.40% |
| 2024-06-30 | $44.68 Million | +52.14% |
| 2023-06-30 | $29.37 Million | +43.84% |
| 2022-06-30 | $20.42 Million | -- |